How the histamine N-methyltransferase inhibitor metoprine alleviates methamphetamine reward

<p>Methamphetamine (METH) is a highly addictive psychomotor stimulant drug that is abused worldwide [1].<br>METH abuse results in numerous adverse effects after acute administration, as well as an array of adverse outcomes associated with binge use, long-term use, and withdrawal [2- 4]....

Full description

Saved in:
Bibliographic Details
Main Authors: Nobue Kitanaka (Author), Junichi Kitanaka (Author), F Scott Hall (Author), Satoshi Okumura# (Author), Tomoyuki Sakamoto# (Author), George R Uhl (Author), Motohiko Takemura (Author)
Format: Book
Published: Journal of Addiction Medicine and Therapeutic Science - Peertechz Publications, 2017-05-12.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_2455-3484_000021
042 |a dc 
100 1 0 |a Nobue Kitanaka  |e author 
700 1 0 |a  Junichi Kitanaka  |e author 
700 1 0 |a  F Scott Hall  |e author 
700 1 0 |a  Satoshi Okumura#  |e author 
700 1 0 |a  Tomoyuki Sakamoto#  |e author 
700 1 0 |a  George R Uhl  |e author 
700 1 0 |a Motohiko Takemura  |e author 
245 0 0 |a How the histamine N-methyltransferase inhibitor metoprine alleviates methamphetamine reward 
260 |b Journal of Addiction Medicine and Therapeutic Science - Peertechz Publications,   |c 2017-05-12. 
520 |a <p>Methamphetamine (METH) is a highly addictive psychomotor stimulant drug that is abused worldwide [1].<br>METH abuse results in numerous adverse effects after acute administration, as well as an array of adverse outcomes associated with binge use, long-term use, and withdrawal [2- 4]. Acutely METH releases dopamine from synaptic terminals through multiple actions that include inducing reverse transport of dopamine via the dopamine transporter (DAT), impairing the function of the vesicular monoamine transporter-2 (VMAT2), leading to increased cytoplasmic dopamine concentrations,<br>and inhibition of monoamine oxidase [5-8]. Moreover, these changes contribute to the production of oxidative metabolites, metabolic impairments, oxidative damage to dopamine terminals, and depletion of tissue dopamine levels [9-11]. METH and related drugs consequently produce broad effects on the central nervous system both acutely and chronically [12-14].<br></p> 
540 |a Copyright © Nobue Kitanaka et al. 
546 |a en 
655 7 |a Review Article  |2 local 
856 4 1 |u https://doi.org/10.17352/2455-3484.000021  |z Connect to this object online.